Acute opioid withdrawal precipitated by ingestion of crushed Embeda (morphine extended release with sequestered naltrexone): Case report and the focused review of the literature

Journal of Opioid Management

Volumn 6, Issue 4, 2010, Pages 300-303

  Ruan, Xiulu ^a,b   Chen, Tao ^c   Gudin, Jeff ^d   Couch, John Patrick ^b,e   Chiravuri, Srinivas ^f  

^a Physician's Pain Specialists of Alabama   (United States)

^b UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^c Interventional Pain Medicine   (United States)

^d ENGLEWOOD HOSPITAL AND MEDICAL CENTER   (United States)

^e University of Michigan Health System ^*  (United States)

^f UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Embeda; Morphine; Naltrexone; Opioid withdrawal

Indexed keywords

ANTIEMETIC AGENT; CLONIDINE; HYDROMORPHONE; MORPHINE; NALTREXONE; OPANA; OXYCODONE; OXYMORPHONE; PROMETHAZINE; UNCLASSIFIED DRUG; DELAYED RELEASE FORMULATION; DRUG COMBINATION; MORPHINE, NALTREXONE COMBINATION; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ADULT; ARTICLE; BLOOD PRESSURE; CASE REPORT; DRUG RELEASE; DRUG TREATMENT FAILURE; DRUG URINE LEVEL; EMERGENCY TREATMENT; HEART RATE; HUMAN; INTERVERTEBRAL DISK DISEASE; LOW BACK PAIN; MALE; OPIOID WITHDRAWAL; PATIENT COMPLIANCE; PATIENT COUNSELING; PUPIL; SWEATING; WITHDRAWAL SYNDROME; ACUTE DISEASE; CHRONIC DISEASE; DELAYED RELEASE FORMULATION; DRUG COMBINATION; MEDICATION COMPLIANCE; MIDDLE AGED; OPIOID-RELATED DISORDERS; SEVERITY OF ILLNESS INDEX; SUBSTANCE WITHDRAWAL SYNDROME;

ACUTE DISEASE; ANALGESICS, OPIOID; CHRONIC DISEASE; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; HUMANS; LOW BACK PAIN; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MORPHINE; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; SEVERITY OF ILLNESS INDEX; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 77957313928     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2010.0028     Document Type: Article

References (21)

1. Embeda (Package Insert). Bristol, TN: King Pharmaceuticals, Inc, 2009.
2. Stauffer J, Setnik, B, Sokolowska M, et al.: Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: A randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig. 2009; 29(12): 777-790.
3. Katz N, Sun S, Johnson F, et al.: ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: Pharmacokinetics, efficacy and safety. J Pain. 2009; 11: 303-311.
4. Sloan P: Review of oral oxymorphone in the management of Pain. Ther Clin Risk Manag. 2008; 4(4): 777-787.
5. Pergolizzi J, Boger RH, Budd K, et al.: Opioids and the management of chronic severe pain in the elderly: Consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008; 8(4): 277-313.
6. Manchikanti L: National drug control policy and prescription drug abuse: Facts and fallacies. Pain Physician. 2007; 10: 399-424.
7. Kuehn BM: Opioid prescription soar: Increase in legitimate use as well as abuse. JAMA. 2007; 297: 249-251.
8. Caudill-Slosberg MA, Schwartz LM, Woloshin S: Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs 2000. Pain. 2004; 109: 514-519.
9. Olsen Y, Daumit GL, Ford DE: Opioid prescriptions by US primary care physicians from 1992 to 2001. J Pain. 2006; 7: 225-235.
10. The American Academy of Pain Medicine, The American Pain Society: The use of opioids for the treatment of chronic pain: A consensus statement from the American Academy of Pain Medicine and American Pain Society. Clin J Pain. 1997; 13: 6-8.
11. Center on Addiction and Subtance Abuse: Substance Abuse and Federal Entitlement Programs. New York: Columbia University, 1995.
12. Office of Applied Studies: Substance Abuse and Mental Health Service Administration: Results from the 2004 National Survery on Drug Use and Health. Rockville, MD: Department of Health and Human Services, 2005.
13. Webster L: Update on abuse-resistant and abuse deterrent approaches to opioid formulations. Pain Med Suppl. 2009; 2: S124-S133.
14. Wick JY: Drug-abuse deterrent formulations. Consult Pharm. 2009; 24(5): 356-362, 365.
15. Boyce SH, Armstrong PAR, Stevenson J: Effect of inappropriate naltrexone use in a heroin misuser. Emerg Med J. 2003; 20: 381-382.
16. Armstrong J, Little M, Murray L: Emergency department presentations of naltrexone-accelerated detoxification. Acad Emerg Med. 2003; 10(8): 860-866. (Pubitemid 37040530)
17. Manelli P, De Risio, Possi G, et al.: Serendipitous rapid detoxification from opiates: The importance of time dependent processes. Addiction. 1999; 94: 589-591.
18. Quigley MA, Boyce SH: Unintentional rapid opioid detoxification. Emerg Med J. 2001; 18: 494-495.
19. Drug Information Online: http://www.drugs.com/pro/naltrexone.html. Accessed July 2009.
20. RxList: The Internet Drug Index. Available at http://www.rxlist.com/ revia-drug.htm. Accessed July 2008.
21. Fishman M: Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone. Addiction. 2008; 103(8): 1399-1401.